disease

(redirected from orphan disease)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
References in periodicals archive ?
The report provides a detailed understanding and analysis of how and why companies enter orphan diseases partnering deals.
However, there are number of issues and barriers unique to developing treatments for orphan diseases that pharmaceutical companies face and which are often not well understood by the general public.
James joins Oxyrane from his previous role as US Head of Regulatory Affairs for rare and orphan diseases at Shire Human Genetic Therapies.
He will also support the further development of our pipeline in orphan diseases.
Data and analysis on the global orphan disease therapeutics in genetic disorders in the leading geographies of the world- the US, the UK, Germany, France, Italy, Spain, and Japan.
GBI Research's analysis of industry trends suggests that the orphan disease therapeutics market is likely to see a steady increase in value over the forecast period.
We also anticipate the potential for a number of federal funding opportunities for SGX301 in this orphan disease, as well as for expansion into other indications of unmet medical need.
GBI Research, the leading business intelligence provider, has released its latest research Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules, which provides insights into the Oncology orphan disease therapeutics market until 2018.
GBI Research, the leading business intelligence provider, has released its latest research Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease Segment, which provides insights into the CNS orphan disease therapeutics market until 2017.
ITP is recognized by the US FDA as an orphan disease, usually defined as a condition that affects fewer than 200,000 people nationwide.
WASHINGTON -- Thought leaders from dozens of biotech and pharmaceutical corporations from across the globe will gather June 19 - 20 to discuss innovations and regulations pertaining to Orphan Diseases, at the 2012 Orphan Disease Forum, as part of the 2012 BIO International Convention in Boston, MA.